Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR4 | P61073 | 6/20 | 0.73 |
| ▸ | KRAS | P01116 | 5/20 | 0.54 |
| ▸ | SSTR2 | P30874 | 2/20 | 0.54 |
| ▸ | F12 | P00748 | 6/20 | 0.54 |
| ▸ | MC4R | P32245 | 1/20 | 0.53 |
| ▸ | MC3R | P41968 | 1/20 | 0.53 |
| ▸ | MC1R | Q01726 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29370908 | 1.00 | CXCR4 (0.73) | CXCR4KRASSSTR2F12MC4R | |
| SCHEMBL31692775 | 1.00 | CXCR4 (0.73) | CXCR4KRASSSTR2F12MC4R | |
| SCHEMBL29466605 | 0.97 | CXCR4 (0.71) | CXCR4KRASSSTR2F12MC4R | |
| SCHEMBL29932137 | 0.97 | CXCR4 (0.77) | CXCR4F12 | |
| SCHEMBL29385707 | 0.97 | CXCR4 (0.77) | CXCR4F12 | |
| SCHEMBL15987184 | 0.97 | CXCR4 (0.77) | CXCR4F12 | |
| SCHEMBL20438937 | 0.96 | CXCR4 (0.68) | CXCR4KRASSSTR2 | |
| SCHEMBL29932187 | 0.94 | CXCR4 (0.64) | CXCR4KRASF12 | |
| Motixafortide SCHEMBL24090760 | 0.93 | CXCR4 (0.65) | CXCR4KRASSSTR2MC4RMC3R | |
| Motixafortide SCHEMBL29367811 | 0.93 | CXCR4 (0.65) | CXCR4KRASSSTR2MC4RMC3R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 65 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12540165-B2 | HSP fusion protein with anti-chemorepellant agent for treatment of cancer | THE GENERAL HOSPITAL CORPORATION (US) | 2026-02-03 | — | — | US | claimed |
| CN-118767162-A | Immobilized enzyme nanogel and preparation method and application thereof | 山东大学 | 2024-10-15 | — | — | CN | claimed |
| CN-117771168-A | Hydrogel for repairing spinal cord injury | 上海市同仁医院 | 2024-03-29 | — | — | CN | claimed |
| CN-116271100-A | Nanometer gel based on immobilized collagenase and preparation method and application thereof | 山东大学 | 2023-06-23 | — | — | CN | claimed |
| US-20220323493-A1 | EX VIVO ANTIGEN-PRESENTING CELLS OR ACTIVATED CD-POSITIVE T CELLS FOR TREATMENT OF CANCER | THE GENERAL HOSPITAL CORPORATION | 2022-10-13 | — | — | US | claimed |
| US-20220275032-A1 | HSP Fusion Protein with Anti-Chemorepellant Agent for Treatment of Cancer | THE GENERAL HOSPITAL CORPORATION | 2022-09-01 | — | — | US | claimed |
| US-11325951-B2 | HSP fusion protein with anti-chemorepellant agent for treatment of cancer | THE GENERAL HOSPITAL CORPORATION (US) | 2022-05-10 | — | — | US | claimed |
| US-20260053790-A1 | TREATMENTS FOR CONDITIONS INVOLVING INCREASED IL-6 LEVELS | X4 PHARMACEUTICALS INC (US) | 2026-02-26 | — | — | US | disclosed |
| EP-4687960-A1 | METHODS OF HEMATOPOIETIC PRECURSOR CELLS MOBILIZATION | BioLineRx Ltd. (IL) | 2026-02-11 | — | — | EP | disclosed |
| US-12540172-B2 | Therapeutic nanoconjugates comprising Stefin A and uses thereof | UNIVERSITAT AUTONOMA DE BARCELONA (UAB) (ES) | 2026-02-03 | — | — | US | disclosed |
| US-12540165-B2 | HSP fusion protein with anti-chemorepellant agent for treatment of cancer | THE GENERAL HOSPITAL CORPORATION (US) | 2026-02-03 | — | — | US | disclosed |
| US-20250361307-A1 | COMBINATION THERAPIES FOR TREATING HYPERPROLIFERATIVE DISORDERS | X4 PHARMACEUTICALS INC (US) | 2025-11-27 | — | — | US | disclosed |
| EP-4642465-A1 | A CANCER ASSOCIATED FIBROBLAST (CAF) INHIBITOR FOR USE WITH AN ALTERNATING ELECTRIC FIELD IN A METHOD OF TREATING DISEASES SUCH AS CANCER | Novocure GmbH (CH) | 2025-11-05 | — | — | EP | disclosed |
| US-20220288155-A1 | CXCR4 INHIBITOR FOR THE TREATMENT OF ACUTE RESPIRATORY DISTRESS SYNDROME AND VIRAL INFECTIONS | BIOLINERX LTD. (IL) | 2022-09-15 | — | — | US | disclosed |
| US-11433136-B2 | Polyacetal polymers, conjugates, particles and uses thereof | THE GENERAL HOSPITAL CORPORATION (US) | 2022-09-06 | — | — | US | disclosed |
| US-20220275032-A1 | HSP Fusion Protein with Anti-Chemorepellant Agent for Treatment of Cancer | THE GENERAL HOSPITAL CORPORATION | 2022-09-01 | — | — | US | disclosed |
| US-11419894-B2 | Modified natural killer cells for the treatment of cancer | THE GENERAL HOSPITAL CORPORATION (US) | 2022-08-23 | — | — | US | disclosed |
| US-11364264-B2 | Ex vivo antigen-presenting cells or activated CD-positive T cells for treatment of cancer | THE GENERAL HOSPITAL CORPORATION (US) | 2022-06-21 | — | — | US | disclosed |
| US-11325951-B2 | HSP fusion protein with anti-chemorepellant agent for treatment of cancer | THE GENERAL HOSPITAL CORPORATION (US) | 2022-05-10 | — | — | US | disclosed |
| US-20220072084-A1 | THERAPEUTIC NANOCONJUGATES AND USES THEREOF | UNIVERSITAT AUTONOMA DE BARCELONA (UAB) (ES) | 2022-03-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11433136-B2 | Polyacetal polymers, conjugates, particles and uses thereof | CD44, FUT6, MSN | CXCR4 2962/4885KRAS 2232/4885SSTR2 3394/4885 |
| US-12540165-B2 | HSP fusion protein with anti-chemorepellant agent for treatment of cancer | HSP90AB2P, HSPA2, CDC37 | CXCR4 452/4885KRAS 3675/4885SSTR2 1465/4885 |
| US-12540172-B2 | Therapeutic nanoconjugates comprising Stefin A and uses thereof | MYOF, MSTN, NGLY1 | CXCR4 3228/4885KRAS 931/4885SSTR2 1930/4885 |
| US-20260053790-A1 | TREATMENTS FOR CONDITIONS INVOLVING INCREASED IL-6 LEVELS | CXCR6, IL6, CCR6 | CXCR4 4/4885KRAS 2458/4885SSTR2 539/4885 |
| US-20250361307-A1 | COMBINATION THERAPIES FOR TREATING HYPERPROLIFERATIVE DISORDERS | CXCR6, BCL6, CXCR4 | CXCR4 3/4885KRAS 642/4885SSTR2 1351/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.